Variables associated with use of symptomatic medication during a headache attack in individuals with tension-type headache:a European study by Fernández-de-Las-Peñas, César et al.
 
  
 
Aalborg Universitet
Variables associated with use of symptomatic medication during a headache attack in
individuals with tension-type headache
a European study
Fernández-de-Las-Peñas, César; Palacios-Ceña, Maria; Castaldo, Matteo; Wang, Kelun;
Guerrero-Peral, Ángel; Catena, Antonella; Arendt-Nielsen, Lars
Published in:
BMC Neurology
DOI (link to publication from Publisher):
10.1186/s12883-020-1624-8
Creative Commons License
CC BY 4.0
Publication date:
2020
Document Version
Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Fernández-de-Las-Peñas, C., Palacios-Ceña, M., Castaldo, M., Wang, K., Guerrero-Peral, Á., Catena, A., &
Arendt-Nielsen, L. (2020). Variables associated with use of symptomatic medication during a headache attack in
individuals with tension-type headache: a European study. BMC Neurology, 20(1), [43].
https://doi.org/10.1186/s12883-020-1624-8
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
RESEARCH ARTICLE Open Access
Variables associated with use of
symptomatic medication during a
headache attack in individuals with
tension-type headache: a European study
César Fernández-de-las-Peñas1,2,3* , Maria Palacios-Ceña1,2, Matteo Castaldo2,4,5, Kelun Wang2,
Ángel Guerrero-Peral6, Antonella Catena4 and Lars Arendt-Nielsen2
Abstract
Background: Pharmacological treatment of patients with tension-type headache (TTH) includes symptomatic
(acute) and prophylactic (preventive) medication. No previous study has investigated variables associated to
symptomatic medication intake in TTH. Our aim was to assess the association of clinical, psychological and
neurophysiological outcomes with the use and timing of the use of symptomatic medication in TTH.
Methods: A longitudinal observational study was conducted. One hundred and sixty-eight (n = 168) patients with
TTH participated. Pain features of the headache (intensity, frequency, duration), burden of headache (Headache
Disability Inventory), sleep quality (Pittsburgh Sleep Quality Index), anxiety/depression (Hospital Anxiety and
Depression Scale), trait/state anxiety levels (State-Trait Anxiety Inventory), and bilateral pressure pain thresholds on
the temporalis, C5-C6 joint, second metacarpal and tibialis anterior were assessed. Symptomatic medication intake
was also collected for a 6-months follow-up period. Differences between patients using or not using symptomatic
medication, depending on self-perceived effectiveness, and time (early during an attack, i.e., the first 5 min, or when
headache attack is intense) when the symptomatic medication was taken were calculated.
Results: One hundred and thirty-six (n = 136, 80%) reported symptomatic medication intake for headache (73%
NSAIDs). Sixteen (12%) reported no pain relief, 81 (59%) experienced moderate relief and 39 (29%) total pain relief.
Fifty-eight (43%) took ‘early medication’ whereas 78 (57%) took ‘late medication’. Patients taking symptomatic
medication in general showed lower headache frequency and lower depressive levels than those patients not
taking medication. Symptomatic medication was more effective in patients with lower headache history, frequency,
and duration, and lower emotional burden. No differences in pressure pain sensitivity were found depending on
the self-perceived effectiveness of medication. Patients taking ‘late symptomatic’ medication exhibited more
widespread pressure pain sensitivity than those taking ‘early medication’.
Conclusions: This study found that the effectiveness of symptomatic medication was associated with better
headache parameters (history, frequency, or duration) and lower emotional burden. Further, consuming early
symptomatic medication at the beginning of a headache attack (the first 5 min) could limit widespread pressure
pain sensitivity.
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Background
Tension-type headache (TTH) is a pain disorder showing
a prevalence of 42% in the general population [1], an im-
portant socio-economic impact [2] and a relevant social
and personal burden [3]. In the last Global Burden of Dis-
ease Study, headache was found to be the second most
prevalent chronic pain condition in the world [4].
Pharmacological treatment of patients with TTH in-
cludes symptomatic (acute) and prophylactic medication.
Symptomatic medication refers to the treatment of a
single headache attack, whereas prophylactic medication
refers to continued treatment used for preventing the
headache attacks. Simple analgesics and non-steroidal anti-
inflammatory drugs (NSAIDs) are the mainstays within the
symptomatic therapy. The clinical practice guideline of
European Federation of Neurological Societies (EFNS) rec-
ommends simple analgesics (i.e., paracetamol) and NSAIDs
(i.e., ibuprofen or aspirin) as first-line for the symptomatic
treatment of TTH, particularly the episodic form [5]. This
recommendation agrees with results from some Cochrane
reviews reporting moderate to high evidence for the use of
paracetamol (1000mg) [6] or ibuprofen (400mg) [7], and
low to moderate evidence for the use of ketoprofen (25mg)
[8] or aspirin (500mg–1000mg) [9], as effective acute med-
ications for episodic TTH. A recent study observed that
NSAIDs consumption in people with TTH almost reached
90% and that patient’s preferences on medication intake
was slightly different from clinical guideline recommenda-
tions [10].
Although the mechanisms underlying TTH are not
completely understood, current evidence supports the
presence of hyper-excitability of the central nervous sys-
tem as an important factor in the development of TTH
pain [11]. Further, several associated factors including
mood disorders (anxiety or depression) [12], sleep distur-
bances [13] or emotional stress [14] can also contribute to
this excitable state. No study has previously investigated
the association of these variables to symptomatic medica-
tion intake in TTH patients. Considering the impact [2]
and personal burden [3] associated to this headache dis-
order, better understanding of the variables associated with
symptomatic medication intake may help to better identify
some critical areas for future research on symptomatic
medication treatment of individuals with TTH. Therefore,
the aim of this longitudinal observational study was to
investigate potential associations of clinical, psychological
and sensitivity outcomes with use of symptomatic medica-
tion in individuals suffering from TTH. We hypothesized
that: 1, taking symptomatic medication would be associ-
ated with less frequent and debilitating headaches, lower
anxiety and depressive levels and less widespread pressure
sensitivity than not taking symptomatic medication; and, 2,
taking symptomatic medication at the beginning of the
headache attack would be associated with less frequent and
debilitating headache, lower levels of anxiety and depres-
sive levels and less widespread pressure pain sensitivity
than taking symptomatic medication when the pain of the
headache attack is intense.
Methods
Study design
The current analysis is included as part of a multicenter
international headache study about medication intake in
TTH. Some patients from the current study were also in-
cluded in a previous study which data have been already
previously published [15]. This previous analysis found
that patients with TTH taking prophylactic medication
(i.e., amitriptyline) had higher frequency and burden of
headaches, worse sleep quality and higher depressive levels
than those TTH patients not taking prophylactic medica-
tion [15]. In addition, prophylactic medication was less
effective in those patients exhibiting generalized pressure
pain sensitivity [15]. The current study presents new data,
different outcomes, and different reasoning.
Patient and public involvement statement
Patients were not involved in the development of the
study design, development of research question or their
recruitment. Results from the study are available to
those participants who requested them.
Participants
Patients with a diagnosis of TTH were recruited from
three different university-based hospitals (University Rey
Juan Carlos, Aalborg University, Parma University) from
September 2014 to January 2017. Diagnosis was done
according to the third edition of the International Classi-
fication of Headache Disorders, (ICHD3 beta, 2013)
down to third-digit level (codes 2.2, 2.3) by a neurologist
expert in headaches [16]. They were excluded if pre-
sented: 1, other primary and/or secondary headache; 2,
medication overuse headache as defined by the ICHD-3
(beta); 3, history of neck or head trauma; 4, any systemic
degenerative disease; 5, diagnosis of fibromyalgia syn-
drome; 6, received anesthetic blocks or botulinum toxin
within the previous 6 months; 7, received physical treat-
ment in the neck and head the previous 6 months; or, 8,
pregnancy. All participants read and signed a consent
form prior to their participation. The local Ethics Com-
mittee approved the study (URJC 23/2014, HUFA 14/
104, Aalborg N20140063, CESU 5/2015).
Headache diary
A headache diary for 4 weeks was used to substantiate
the diagnosis and to record the clinical features at base-
line [17]. On the diary, patients registered the frequency
of headaches (days/week), the headache intensity on an
11-points numerical pain rate scale [18] (NPRS; 0: no
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pain, 10: the maximum pain), and the duration of the
headache attack (hours/day). Patients monitored their
medication intake in a diary for a 6 months period. Pa-
tients regularly taking symptomatic medication for at
least 30% of their headache attacks during this period
were considered as ‘taking medication intake’. In this
diary, they registered if the symptomatic medication
drug used for headache (when taken); the time when
they take the medication: ‘early symptomatic’ (at the be-
ginning of the attack, in the first 5 min) or ‘late symp-
tomatic’ (when the headache was intense, defined as > 7
on a NPRS); and the self-perceived effectiveness of the
medication (i.e., absent, moderate or total pain relief at
2 h without the use of other medication) [19]. Absent re-
lief was defined as no effect or a reduction of less than
20% in the intensity of the headache; moderate pain re-
lief was defined as a reduction of 50% of the intensity of
the headache; whereas total pain relief was defined as a
reduction of more than 80% of the headache intensity.
Anxiety and depressive symptoms
The Hospital Anxiety and Depression Scale (HADS) is a
14-items self-report screening scale indicating the pres-
ence of anxiety and depressive symptom [20]. It consists
of 7 items for evaluating anxiety (HADS-A) and 7 for
depression (HADS-D). Each item scores on a Likert
scale (0–3) giving a maximum score of 21 points for
each subscale [21]. The HADS has shown good validity
and internal consistency for being used in subjects with
headache [22]. Anxiety and depressive symptoms were
assessed at baseline.
Trait and state anxiety levels
The State-Trait Anxiety Inventory (STAI) is a 40-items
self-report scale assessing state (items l-20, STAI-S)
and trait (items 21–40, STAI-T) levels of anxiety [23,
24]. The STAI-S items assess relatively enduring symp-
tom of anxiety whereas the STAI-T items measures a
stable propensity to experience anxiety, and tendencies
to perceive stressful situations as threatening. Both sub-
scales have shown good internal consistency scores
[25]. In both scales, higher scores indicate greater state
or trait anxiety. State and trait levels of anxiety were
assessed at baseline.
Burden of headache
The Headache Disability Inventory (HDI) was used to
evaluate headache burden. This questionnaire uses 25-
items that inquire about the perceived impact of head-
ache on emotional functioning and daily life activities
[26]. Thirteen items assess emotional burden (HDI-E,
maximum score: 52) and 12 items assess physical burden
(HDI-P, maximum score: 48). A greater score indicates a
higher burden of headache. The HDI exhibits good
stability in patients with headache [27]. The HDI was
assessed at baseline.
Sleep quality
The Pittsburgh Sleep Quality Index (PSQI) was used to
assess sleep quality over the previous month by includ-
ing 19 self-rated questions and 5 questions answered by
bed- or room- mates [28]. The total score ranges from 0
to 21 where higher score indicates worse quality of sleep.
This questionnaire has good internal consistency and
test-retest reliability [29, 30]. Sleep quality was assessed
at baseline.
Pressure pain sensitivity
An electronic pressure algometer (Somedic® Algometer,
Sollentuna, Sweden) was used to bilaterally assess pres-
sure pain thresholds (PPT) over the temporalis muscle,
the C5-C6 joint, the second metacarpal and the tibialis
anterior muscle. PPT is defined as the minimal amount
of pressure where a sense of pressure changes to pain.
Pressure was increased at a rate of approximately 30
kPa/s. The mean of 3 trials on each point, with a 30s
resting period for avoiding temporal summation of pain
[31] was calculated and used for the main analyses. The
order of assessment was randomized between subjects
and the assessor was blinded to other outcomes. Partici-
pants practiced first on the wrist extensors of the right
forearm. The reliability of pressure algometry has been
found to be high [32]. Pressure pain sensitivity was
assessed at baseline.
Statistical analysis
Means and confidence intervals were calculated to describe
the outcomes. The Kolmogorov-Smirnov test revealed that
all quantitative data had a normal distribution (P > .05).
Patients were grouped by use or not use of symptomatic
medication, by those taking the medication as ‘early symp-
tomatic’ or as ‘late symptomatic’, and by the self-rated
effectiveness of the medication (absent, moderate or total
pain-relief). Differences between grouped patients in clinical
features, burden of headache (HDI-E, HDI-P), depression
(HADS-D), anxiety (HADS-A, STAI-T, STAI-S) and sleep
quality (PSQI) were compared using one-way analysis of
variance (ANOVA). Also, a 2-way ANOVA was used to
evaluate the differences in PPTs with side as within-
subjects factor and group as between-subjects factor. The
normality and homogeneity criteria were checked for the
dependent variables with Kurtosis and Skewness for the
normality and Levene’s test for the homogeneity criteria.
Separate ANOVAs were performed for each variable.
Regression analysis were conducted to determine that the
differences observed with the ANOVA remained sig-
nificant after the inclusion of multiple comparisons.
As multiple comparisons were conducted in the main
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analysis, a Bonferroni-corrected alpha level of 0.025 (2
independent-samples t-tests) was required accept sta-
tistically significance.
Results
Clinical data of the sample
A total of 220 individuals with headache were screened
for possible eligibility criteria. Finally, 170 patients (73%
women) satisfied all the eligibility criteria, agreed to par-
ticipate and signed the written informed consent. Fifty
(n = 50) were excluded for: co-morbid migraine (n = 25),
previous whiplash injury (n = 10), medication overuse
headache (n = 10) and fibromyalgia (n = 5). One hundred
and sixty-eight (n = 168, 99%) were finally included in
the analysis as they returned the headache diary with
medication intake data. One hundred and sixty (n = 160,
95%) were diagnosed with TTH associated to pericranial
tenderness whereas the remaining 8 (5%) were not asso-
ciated to pericranial tenderness. Demographic data and
outcome measure scores are listed in Table 1.
Taking symptomatic or not taking symptomatic medication
One hundred and thirty-six (81%) reported taking symp-
tomatic medication for their headache: 62 (45.5%) took
simple analgesics (paracetamol) whereas the remaining 74
(54.5%) took NSAID (ibuprofen: n = 57, 42%; ketoprofen:
n = 7, 5%; naproxen: n = 10, 7.5%). Patients reported that
they took symptomatic medication in 70% of the headache
attacks (mean 8.8 ± 1 headache per month), not in all.
Significant differences in the distribution of individuals
with frequent episodic (FETTH) and chronic (CTTH)
tension-type headache (P = 0.021), headache frequency
(P = 0.015) and depression (HADS-D, P = 0.021) were
observed between patients taking or not taking symp-
tomatic medication. Post hoc analysis revealed a higher
proportion of FETTH patients, those with lower fre-
quency of headaches, or lower depressive levels within
the symptomatic medication intake group (Table 1). The
regression analysis also showed the same significant dif-
ferences between those individuals taking or not taking
symptomatic medication (Additional file 1: Table S1).
No differences in gender (P = 0.63), age (P = 0.26), head-
ache history (P = 0.8), headache intensity (P = 0.3), head-
ache duration (P = 0.6), HADS-A (P = 0.345), STAI-T
(P = 0.739), STAI-S (P = 0.591), HDI-P (P = 0.791), HDI-
E (P = 0.117) and PSQI (P = 0.631) were found between
patients taking or not taking symptomatic medication
(Table 1). Similarly, no significant differences in sensitiv-
ity to pressure pain were either reported (C5-C6: F =
0.882, P = 0.349; temporalis muscle: F = 0.109, P = 0.742),
second metacarpal (F = 0.455, P = 0.501), or tibialis an-
terior muscle (F = 1.212, P = 0.385) (Table 2).
Table 1 Clinical features, psychological and related-disability outcomes in patients with tension-type headache in the total sample
and by symptomatic medication intake (n = 168)
Total sample (n = 168) Taking medication (n = 136) No taking medication (n = 32)
Clinical Pain Features
Gender (male/female) n (%) 45 (27%) / 123 (73%) 36 (27%) / 100 (73%) 9 (31%) / 23 (72%)
FETTH / CTTH n (%)a 94 (56%) / 74 (44%) 82 (60%) / 54 (40%) 12 (38%) / 20 (62%)
Age (years) 46 (44, 48) 45 (42, 48) 48 (43, 53)
Headache history (years) 10.5 (8.9, 12.1) 10.8 (8.8, 12.8) 10.2 (7.1, 13.3)
Headache intensity (0–10) 6.1 (5.7, 6.5) 6.0 (5.4, 6.6) 6.6 (5.8, 7.4)
Headache frequency (days/month) a 16.7 (12.5, 20.9) 16.2 (14.0, 18.4) 19.3 (17.8, 20.8)
Headache duration (hours per attack) 7.3 (6.6, 8.0) 7.2 (6.4, 8.0) 7.6 (6.0, 9.2)
Prophylactic medication n (%) 40 (25%) 16 (12%) 24 (75%)
Psychological and disability-related outcomes
HADS-D (0–21) a 8.4 (7.7, 9.1) 7.5 (6.7, 8.3) 9.5 (8.0, 11.0)
HADS-A (0–21) 10.7 (9.7, 11.7) 10.7 (9.8, 11.6) 10.6 (9.0, 12.2)
HDI-P (0–48) 23.0 (21.8, 24.2) 22.5 (20.2, 24.8) 23.2 (18,6, 27.8)
HDI-E (0–52) 19.7 (17.5, 21.9) 18.0 (15.5, 20.5) 22.2 (16.5, 27.9)
STAI-T (0–60) 23.9 (22.7, 25.1) 23.8 (22.4, 25.2) 24.2 (21.3, 27.3)
STAI-S (0–60) 21.8 (20.8, 22.8) 21.6 (20.5, 22.7) 22.2 (20.3, 24.1)
PSQI (0–21) 8.0 (7.2, 8.8.) 8.2 (7.5, 8.9) 7.8 (5.8, 9.8)
Values are expressed as means (95% confidence interval); a Significant differences between groups (ANOVA, P < 0.025)
FETTH Frequent episodic tension type headache; CTTH Chronic tension type headache; HADS Hospital Anxiety and Depression Scale (D Depression; A Anxiety), HDI
Headache Disability Inventory (P Physical; E Emotional), STAI State-Trait Anxiety Inventory (T Trait; S State); PSQI Pittsburgh Sleep Quality Index
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Self-reported effectiveness of symptomatic treatment
Sixteen (12%) patients reported no pain relief, other 81
(59%) get moderate pain relief, whereas 39 (29%) experi-
enced total pain relief with acute medication. Significant
differences in the distribution of patients with FETTH and
CTTH (P = 0.023), headache history (F = 4.317, P = 0.015),
headache duration (F = 7.578, P = 0.001), headache fre-
quency (F = 9.627, P < 0.001) or emotional burden of
headache (HDI-E: F = 4.945, P = 0.009) were observed de-
pending on the self-rated effectiveness of symptomatic
medication: a higher proportion of FETTH patients, those
with a shorter headache history, shorter duration of head-
ache attacks, lower headache frequency or lower emo-
tional burden of the headache reported total pain relief
with symptomatic medication intake (Table 3). For regres-
sion analysis, patients were grouped as total pain relief or
no total pain relief (no pain relief and moderate pain relief
together). Again, the regression analysis revealed signifi-
cant differences according to the effects of symptomatic
medication (Additional file 1: Table S2).
No differences in gender (P = 0.673), age (P = 0.659),
headache intensity (P = 0.609), HADS-A (P = 0.474), STAI-
T (P = 0.800), STAI-S (P = 0.615), HDI-P (P = 0.467), PSQI
(P = 0.155) and PPTs (C5-C6: F = 0.313, P = 0.732; tempor-
alis muscle: F = 0.416, P = 0.661; second metacarpal: F =
1.460, P = 0.236, or tibialis anterior muscle: F = 0.110, P =
0.896) were found depending on the self-reported effective-
ness of the symptomatic medication (Tables 3 and 4).
Table 2 Pressure pain thresholds (PPT, kPa) between individuals with tension-type headache by symptomatic medication intake
(n = 168)
Temporalis muscle C5-C6 zygapophyseal joint Second metacarpal Tibialis anterior muscle
Taking medication (n = 136)
Right side 210.4 (193.5, 227.3) 204.8 (185.0, 224.6) 248.3 (231.0, 265.6) 402.8 (368.1, 437.5)
Left side 191.9 (177.2, 206.6) 197.5 (180.0, 215.0) 240.0 (223.0, 257.0) 394.1 (360.0, 428.2)
No taking medication (n = 32)
Right side 220.8 (192.8, 248.8) 209.9 (179.8, 240.0) 272.7 (237.0, 308.5) 428.8 (367.2, 490.4)
Left side 199.7 (167.8, 231.6) 195.5 (162.0, 229.0) 260.3 (227.0, 293.6) 434.8 (368.0, 501.6)
Values are expressed as means (95% confidence interval)
Table 3 Clinical features, psychological and related-disability outcomes in patients with tension-type headache depending on the
self-reported perception of pain relief with medication (n = 136)
No Relief (n = 16) Moderate Relief (n = 81) Total Relief (n = 39)
Clinical Pain Features
Gender (male/female) n (%) 5 (31%) / 11 (69%) 22 (27%) / 59 (73%) 9 (23%) / 30 (77%)
FETTH / CTTH n (%)a 10 (62%) / 6 (38%) 40 (49%) / 41 (51%) 32 (82%) / 7 (18%)
Age (years) 44 (40, 48) 47 (44, 52) 46 (42, 50)
Headache history (years) a 13.5 (9.6, 17.4) 9.8 (7.5, 12.1) 4.2 (2.1, 6.3)
Headache intensity (0–10) 6.0 (5.5, 6.5) 6.2 (5.8, 6.6) 6.0 (5.5, 6.5)
Headache frequency (days/) a 18.2 (13.5, 22.9) 19.0 (17.2, 20.8) 11.8 (8.4, 15.2)
Headache duration (hours per attack) a 9.2 (7.2, 11.2) 8.1 (7.1, 9.1) 5.2 (4.0, 6.4)
Psychological and disability-related outcomes
HADS-D (0–21) 8.9 (5.7, 12.1) 8.4 (7.4, 9.4) 7.7 (6.4, 9.0)
HADS-A (0–21) 9.8 (6.7, 12.9) 9.9 (8.9, 10.9) 11.0 (9.7, 12.3)
HDI-P (0–48) 24.0 (20.7, 27.3) 24.1 (21.2, 27.0) 21.1 (17.1, 25.1)
HDI-E (0–52) a 26.6 (20.4, 32.8) 20.8 (17.8, 23.8) 14.7 (10.7, 18.7)
STAI-T (0–60) 23.1 (19.9, 26.3) 23.8 (22.3, 25.3) 24.4 (22.0, 26.8)
STAI-S (0–60) 20.8 (16.8, 24.8) 21.5 (20.4, 22.6) 22.4 (20.7, 24.1)
PSQI (0–21) 7.0 (5.2, 8.8) 8.8 (7.8, 9.8) 7.3 (6.1, 8.5)
Values are expressed as means (95% confidence interval);
a Significant differences between the total relief group and no or moderate relief group (ANOVA, P < 0.025)
FETTH Frequent episodic tension type headache; CTTH Chronic tension type headache; HADS Hospital Anxiety and Depression Scale (D Depression; A Anxiety), HDI
Headache Disability Inventory (P Physical; E Emotional), STAI State-Trait Anxiety Inventory (T Trait; S State); PSQI Pittsburgh Sleep Quality Index
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Taking ‘early symptomatic’ or ‘late symptomatic’
medication
Fifty-eight (43%) reported taking ‘early symptomatic’
medication, whereas the remaining 78 (57%) took ‘late
symptomatic’ medication. No differences were observed
for any clinical or psychological outcome (FETTH/
CTTH: P = 0.359; gender: P = 0.323; age: P = 0.545; head-
ache history: P = 0.181; headache intensity: P = 0.914:
headache duration: P = 0.68; headache frequency: P =
0.160; HADS-D: P0.443; HADS-A: P = 0.930; STAI-T:
P = 0.675; STAI-S: P = 0.627; HDI-P: P = 0.366; HDI-E:
P = 0.523; PSQI: P = 0.33) between patients depending
on the time of the medication intake (Table 5). Signifi-
cant differences in pressure pain sensitivity over the
temporalis (F = 6.243, P = 0.014), second metacarpal (F =
5.731, P = 0.018) and tibialis anterior (F = 5.667, P =
0.019), but not over C5-C6 joint (F = 4.803, P = 0.030)
were observed: individuals taking ‘late symptomatic’
medication exhibited more widespread pressure pain
hypersensitivity than those patients taking ‘early symp-
tomatic’ medication (Table 6). The regression analysis
confirmed the association of lower PPTs (higher pres-
sure pain sensitivity) in those patients taking ‘late symp-
tomatic’ medication (Additional file 1: Table S3).
Table 4 Pressure pain thresholds (PPT, kPa) in individuals with tension-type headache depending on the self-reported perception of
pain relief with medication (n = 136)
Temporalis muscle C5-C6 zygapophyseal joint Second metacarpal Tibialis anterior muscle
No Relief (n = 16)
Right side 220.6 (201.4, 239.8) 221.9 (191.9, 251.9) 288.0 (264.1, 311.9) 415.7 (381.5, 449.9)
Left side 215.4 (194.4, 236.4) 215.6 (182.1, 249.1) 284.1 (254.4, 313.8) 424.9 (395.4, 454.4)
Moderate Relief (n = 81)
Right side 215.7 (197.4, 234.0) 208.9 (184.8, 233.0) 253.6 (234.5, 272.7) 416.5 (377.2, 455.8)
Left side 194.8 (177.8, 211.8) 205.6 (183.8, 227.4) 243.4 (224.4, 262.4) 400.6 (364.4, 436.8)
Total Relief (n = 39)
Right side 217.1 (190.8, 243.4) 198.2 (175.2, 221.3) 238.9 (210.2, 267.6) 417.8 (379.8, 455.8)
Left side 198.3 (179.4, 217.2) 193.4 (171.9, 214.9) 231.9 (210.2, 253.6) 404.7 (367.6, 441.8)
Values are expressed as means (95% confidence interval)
Table 5 Clinical features, psychological and related-disability outcomes in patients with tension-type headache depending on the
time when the symptomatic medication intake (n = 136)
Early medication (n = 58) Late medication (n = 78)
Clinical Pain Features
Gender (male/female) n (%) 16 (27%) / 42 (73%) 20 (26%) / 58 (74%)
FETTH / CTTH n (%) 38 (65%) / 20 (35%) 44 (56%) / 34 (46%)
Age (years) 45 (42, 48) 45 (41, 49)
Headache history (years) 12.5 (9.0, 15.0) 9.8 (7.4, 12.2)
Headache intensity (0–10) 6.0 (5.5, 6.5) 6.0 (5.6, 6.4)
Headache frequency (days/) 14.9 (12.6, 17.2) 17.0 (15.2, 18.8)
Headache duration (hours per attack) 7.4 (6.2, 8.6) 7.1 (6.1, 8.1)
Psychological and disability-related outcomes
HADS-D (0–21) 7.1 (6.0, 8.2) 7.7 (7.0, 8.4)
HADS-A (0–21) 10.6 (9.2, 11.0) 10.8 (10.0, 11.6)
HDI-P (0–48) 23.9 (20.0, 27.8) 22.0 (19.7, 24.3)
HDI-E (0–52) 18.9 (15.3, 22.5) 17.4 (14.6, 20.2)
STAI-T (0–60) 23.4 (21.3, 25.5) 24.0 (22.3, 25.7)
STAI-S (0–60) 21.2 (19.8, 22.6) 21.7 (20.3, 23.1)
PSQI (0–21) 7.7 (6.5, 8.9) 8.5 (7.4, 9.6)
Values are expressed as means (95% confidence interval)
FETTH Frequent episodic tension type headache; CTTH Chronic tension type headache; HADS Hospital Anxiety and Depression Scale (D Depression; A Anxiety), HDI
Headache Disability Inventory (P Physical; E Emotional), STAI State-Trait Anxiety Inventory (T Trait; S State); PSQI Pittsburgh Sleep Quality Index
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Discussion
This is the first study investigating variables associated
with the use of symptomatic medication intake in patients
with TTH and when the medication is taken (early or late
during the headache attack). The use of symptomatic
medication was associated with a lower headache fre-
quency and lower depressive symptoms, but not to other
clinical or psychological outcomes, in TTH. Patients with
lower frequency and shorter duration of the headaches,
shorter headache history, and lower emotional headache
burden self-experienced better effects of symptomatic
medication. Individuals taking symptomatic medication at
the beginning of the headache (‘early symptomatic medi-
cation’) presented lower widespread pressure pain sensi-
tivity than those taking the medication when the headache
is intense (‘late symptomatic medication’).
Symptomatic medication in TTH
In our study, 81% of our sample of patients with TTH
reported taking medication for their headache attacks,
data similar to a recent study conducted in Italy where
90% of individuals with TTH were symptomatic medica-
tion users [10]. In the current study, 45.5% of the
patients took simple analgesics (i.e., paracetamol) and
54.5% took NSAID particularly ibuprofen. These data
are similar to those previously reported by Affaitati et al.
[10] and also agree with the recommendations from
international guidelines [5].
Individuals with lower frequency of headaches, that is,
those with more episodic attacks, tend to use symptom-
atic medication in a greater proportion than those with
CTTH. Our data agree with a previous study reporting
that chronic headache sufferers are more likely to use
opioid-combination analgesics, but less likely to use
paracetamol, aspirin or ibuprofen, than episodic head-
ache subjects [33]. It seems that medication intake pat-
terns may be different between patients with chronic or
episodic headaches.
Interestingly, no differences in anxiety levels, headache
burden, sleep quality or widespread pressure pain sensi-
tivity were observed depending on the use or not use of
symptomatic medication. However, we found that indi-
viduals taking acute medication showed lower depressive
levels than those not taking medication. This finding
may be related to the fact that depression is associated
with headache frequency; therefore, individuals with
lower headache frequency tend to exhibit lower depres-
sive levels [34].
Self-perceived effectiveness of symptomatic medication
intake
In our study, 30% of patients with TTH taking symp-
tomatic medication reported total pain relief, which
agree with current data on effectiveness of acute medica-
tion [6–9]. Symptomatic medication was more effective
in those patients with lower frequency and shorter
duration of headaches, shorter history of pain, and lower
emotional burden of headache. It seems that higher fre-
quency of headache [35] and emotional factors [36] can
lead to hyperalgesic response to the central nervous
system; therefore, symptomatic medication may be more
effective in patients with lower central sensitization.
However, we did not observe differences in widespread
pressure pain sensitivity, a manifestation of central
sensitization, based on self-perceived effects of symp-
tomatic medication. It is possible that several pain mech-
anisms are involved in the effectiveness of symptomatic
medication in patients with TTH.
Early or late taking symptomatic medication during the
attack
An important finding of this study was that patients taking
symptomatic medication at the beginning of the headache
attack (‘early symptomatic medication’) showed lower
widespread pressure pain sensitivity than those subjects
taking the medication when the headache was intense
(‘late symptomatic medication’). The presence of wide-
spread sensitivity to pressure pain is a manifestation of
central sensitization [11]. It has been suggested that long-
lasting nociception are responsible for sensitization of the
central nervous system and/or impaired supra-spinal
modulation of the incoming stimuli, and the development
Table 6 Differences in pressure pain thresholds (PPT, kPa) in individuals with tension-type headache depending on the time when
the symptomatic medication intake (n = 136)
Temporalis musclea C5-C6 zygapophyseal joint Second metacarpala Tibialis anterior muscle a
Early medication (n = 58)
Right side 231.5 (201.4, 261.6) 228.4 (192.3, 264.5) 268.7 (237.5, 299.9) 449.7 (385.5, 513.9)
Left side 202.4 (176.7, 228.1) 219.9 (186.4, 253.4) 257.6 (227.6, 287.6) 441.7 (376.8, 506.6)
Late medication (n = 78)
Right side 194.5 (176.2, 212.8) 185.4 (167.5, 203.3) 232.8 (212.3, 253.3) 358.2 (322.0, 394.4)
Left side 183.0 (167.0, 199.0) 180.5 (162.8, 198.2) 227.3 (207.3, 247.3) 359.5 (324.3, 394.7)
Values are expressed as means (95% confidence interval)
a Significant differences between both groups (2-two way ANOVA test, P < 0.025)
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of central sensitization [11]. It is possible that taking the
symptomatic medication at the beginning of the headache
attack (i.e., during the first 5 min) could prevent central
sensitization by decreasing peripheral nociception, lessen-
ing the barrage to the central nervous system. This
hypothesis agrees with the underlying mechanisms of
symptomatic medication since either NSAID or paraceta-
mol inhibits production of prostaglandins [37]. Since pros-
taglandins play a role in nociceptive process, early intake
of symptomatic medication may reduce nociceptive
barrage to the central nervous system. Further, this mech-
anism may be not associated with hypoalgesic effects
induced by symptomatic medication, since widespread
pressure sensitivity was not associated to self-perceived
effectiveness of symptomatic medication. Future studies
investigating the potential underlying mechanisms of clin-
ical and neurophysiological changes related to medication
intake are needed. Additionally, current results open
future clinical trials for investigating the effects of symp-
tomatic medication parameters analyzed in this study in
central sensitization in people presenting with TTH.
Finally, patients should be educated to an ‘early’ symptom-
atic medication intake in clinical practice for decreasing
potential central sensitization.
Strength and limitations
Although strengths of the current study include a large
sample size, the inclusion of patients accordingly to re-
stricted diagnostic criteria and the use of diagnostic diary
some limitations should be also recognized. First, although
the sample size was large, a sample size calculation was
not possible; therefore, it is possible that some compari-
sons could have been underestimated. Second, we in-
cluded patients with TTH from tertiary headache centers;
therefore, results may be not representative of the general
population. Nevertheless, prevalence of symptomatic
medication intake observed in our study was similar to
previous population-based studies. In addition, subjects
suffering from TTH seen in a tertiary center usually also
exhibit coexisting migraine symptoms; although diagnosis
of concomitant primary headaches was carefully excluded.
Another potential limitation in relation to our data on
symptomatic medication intake was the time period for
consider as ‘early symptomatic medication’ (5min) which
can be slightly restricted. Third, data for depression and
sleep quality were smaller than expected, which could be
related to the questionnaires used in the study. For in-
stance, the HADS is considered a screening rather than a
diagnostic instrument for depressive symptoms with a
tendency to underestimate its prevalence [38]. We do not
know if the use of other instruments could lead to differ-
ent results. In fact, it should be considered that most out-
comes were self-reported and their psychometric data in
the languages involved ion this study, e.g., Dutch, Spanish,
Italian, have not been completely determined. Finally, we
do not know if the identified associations will maintain
with longer follow-ups since symptomatic medication in-
take patterns could change with time in TTH.
Conclusions
This study found that the use of symptomatic acute medi-
cation for TTH was associated with a lower headache fre-
quency and lower depressive symptoms, but not to other
clinical/psychological outcomes. Higher effectiveness of
symptomatic medication was associated with lower fre-
quency and shorter duration of the headaches, shorter
headache history, and lower emotional headache burden.
Finally, early intake of the symptomatic medication, i.e., at
the beginning of the headache attack, was associated with
lower widespread pressure pain hypersensitivity.
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